EliquisTablets 5mg, 60 count bottle, Rx Only, Marketed by: Bristol-Meyers Squibb Company Princeton, NJ 08543 USA and Pfizer Inc. New York, NY 10017 USA, NDC 0003-0894-21
Published July 19, 2017 · Recall initiated: June 5, 2017
Summary
FDA records drug Class I recall D-0959-2017, published July 19, 2017 and initiated June 5, 2017. Recalling firm: Bristol-myers Squibb Company; Status: Terminated; Reported quantity: 48,180 bottles; Lot: Lot: HN0063, EXP. 09/2019. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets.
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Bristol-myers Squibb Company
- Distributor
- Nationwide in the US
- Lot
- Lot: HN0063, EXP. 09/2019
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZenecaJuly 19, 2017
- FDAPaliperidone Extended-Release Tablets, 3 mg, 90 count bottles, Rx only, Manufactured by: Actavis LaboratoriesJuly 19, 2017
- FDA0.9% Sodium Chloride Injection USP, 250 mL VIAFLEX Container bag, Rx only, Baxter Healthcare Corporation,July 19, 2017
- FDAKombiglyze XR (saxagliptin and metformin HCl extended-release) tablets, Physician Sample-Not For Sale, 7October 31, 2012
- FDAKombiglyze XR (saxagliptin and metformin HCl extended-release) tablets, Physician Sample-Not For Sale, 6October 31, 2012
- FDABiCNU (Carmustine for injection) 100 mg and Diluent Rx Only BiCNU manufactured by: Ben Venue Laboratories,October 31, 2012
Questions about this recall
Was EliquisTablets 5mg, 60 count bottle, Rx Only, Marketed by: Bristol-Meyers Squibb Company Princeton, NJ 08543 USA and Pfizer Inc. New York, NY 10017 USA, NDC 0003-0894-21 recalled?
Yes. FDA published recall D-0959-2017 on July 19, 2017. Reported hazard: Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets.
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail